Sesame Summit 2026 – application open

Artios raises €105.8M Series D for cancer drug development

European biotech is experiencing unprecedented momentum in oncology innovation, with investors increasingly backing companies developing novel cancer therapeutics. The latest validation comes from Artios, which has secured €105.8M ($115M) in Series D funding to advance its pioneering DNA damage response therapies through clinical trials.

The Cambridge-based biotech represents a new generation of precision oncology companies emerging from Europe’s thriving life sciences ecosystem. Founded in 2016, Artios has built a differentiated platform targeting DNA damage response pathways – an approach that could unlock treatment options for cancers that have proven resistant to conventional therapies.

Strategic investors back cancer drug development

The Series D round was co-led by SV Health Investors and RA Capital Management, two heavyweights in healthcare investing known for backing breakthrough therapeutics. SV Health Investors, with over $8 billion in assets under management, has a particular focus on European biotech companies with global potential. Their participation signals confidence in Artios’ ability to compete with US-based cancer drug developers.

“Artios represents exactly the kind of differentiated science we seek in our European portfolio,” noted a partner at SV Health Investors. “Their DNA damage response platform addresses a significant unmet medical need, and the team has demonstrated exceptional execution in advancing multiple programmes through early clinical development.”

The investor syndicate reflects the cross-border nature of modern biotech financing, combining European expertise with global capital. This €105.8M injection brings Artios’ total funding to over €200M, positioning the company among Europe’s most well-capitalised cancer drug developers.

Advancing first-in-class oncology pipeline

Unlike traditional chemotherapy approaches, Artios targets specific DNA repair mechanisms that cancer cells exploit for survival. This precision approach potentially offers improved efficacy with reduced side effects – a critical advantage in oncology where treatment tolerability often limits patient outcomes.

The funding will accelerate clinical development of the company’s lead programmes, including ART4215, currently in Phase I trials for solid tumours. Artios plans to initiate multiple Phase II studies across different cancer types, leveraging biomarker-driven patient selection to optimise treatment responses.

“This financing enables us to advance our most promising candidates towards registration-enabling studies,” explained Artios CEO Dr. Niall Martin. “We’re particularly excited about the potential to address cancers where current treatment options remain limited, offering new hope to patients and their families.”

The Series D proceeds will also fund expansion of Artios’ Cambridge headquarters and strengthen its intellectual property portfolio around DNA damage response therapeutics.

This significant funding milestone reinforces Europe’s position as a global hub for innovative cancer drug development. With regulatory pathways increasingly aligned between European and US markets, companies like Artios are well-positioned to capture value from breakthrough oncology innovations.

you might also like

Fundraising 3 hours ago

London-based AI laboratory Ineffable Intelligence has emerged from stealth with a $1.1 billion seed round at a $5.1 billion post-money valuation, the company confirmed on 27 April 2026. The financing is the largest seed round ever raised by a European company and one of the largest first-money-in rounds in the global history of artificial intelligence. The round was co-led by Sequoia Capital and Lightspeed Venture Partners. Participating investors included Nvidia, DST Global, Index Ventures, Google, and the UK Sovereign AI Fund, the British government’s recently established vehicle for backing strategic AI capacity on home soil. A bet on a different path to general intelligence Ineffable Intelligence was founded in 2025 by David Silver, the former Vice President of Reinforcement Learning at Google DeepMind and the principal architect of AlphaGo, AlphaZero and AlphaStar. He is joined by three further DeepMind alumni: Wojciech Czarnecki, Lasse Espeholt and Junhyuk Oh. All four have spent the past decade at the frontier of reinforcement learning research, the discipline behind some of the most consequential demonstrations of machine learning over the past ten years. The company describes its objective as building a “superlearner” — an AI system capable of acquiring knowledge directly from its own experience rather than from human-generated text or imagery. “Our mission is to make first contact with superintelligence,” Silver said in a statement accompanying the launch. “We are creating a superlearner that discovers all knowledge from its own experience, from elementary motor skills through to profound intellectual breakthroughs.” The framing is a deliberate departure from the dominant industry trajectory. Most leading AI laboratories, including OpenAI, Anthropic and Google DeepMind itself, have built large language models trained primarily on the corpus of the internet, then refined that training with human feedback. Ineffable’s wager is that the marginal returns on scaling text-based pretraining are diminishing and that the next leap in capability will come from agents that learn endlessly from the consequences of their own actions, in much the same way AlphaZero learnt the game of Go without studying any human matches. Why $1.1 billion at seed The size of the round is unusual even by the inflated standards of the 2026 AI capital cycle. Two factors appear to explain it. First, frontier reinforcement learning at the scale Ineffable describes is computationally extraordinarily expensive: the company will need to operate vast simulation environments and train very large models against them, an undertaking that consumes capital at a rate closer to physical R&D than to traditional software. Second, the round signals a strategic move by Europe’s investor and policy ecosystems to retain the most ambitious AI researchers on the continent. The presence of the UK Sovereign AI Fund alongside Sequoia, Lightspeed and Nvidia is the clearest expression of that intent. The British government has publicly framed the investment as a bet on breakthrough AI that “can discover new knowledge”, positioning the country as a willing co-investor in domestic frontier laboratories. For Ineffable, the implication is access not only to capital but to compute, regulatory engagement and the still-resilient academic talent base around UCL, Oxford, Cambridge and Imperial. Founder pledge of historic scale Alongside the funding announcement, Silver disclosed that he is committing 100 per cent of any personal proceeds from his Ineffable equity to charity via the Founders Pledge network — described by the organisation as the largest pledge in its history. At the round’s $5.1 billion valuation, that commitment could ultimately exceed several billion dollars if the company succeeds. It is a meaningful gesture in a sector where the reputational stakes around concentrated AI wealth are escalating, and one likely to be referenced in subsequent founder-led commitments. Implications for the European AI landscape Ineffable’s emergence reshapes the European AI map in three concrete ways. It establishes London as the home of the continent’s largest-ever seed-stage company, complicating Paris’s recent narrative of frontier-AI primacy after Mistral’s earlier rounds. It validates a thesis — that reinforcement learning, not transformer scaling, is the next frontier — that has lately been losing capital share to language-model incumbents. And it confirms that the UK government is now willing to act as a balance-sheet co-investor in domestic AI laboratories, a posture much closer to the French model than to the predominantly grant-based regimes elsewhere in Europe. The execution risk is non-trivial. Reinforcement learning at frontier scale has historically required years of careful environment design before producing competitive systems, and Ineffable’s “first contact” framing sets a high bar against which it will be judged. But for now, with a billion dollars on the balance sheet, four of the discipline’s most accomplished researchers in the founding team and a sovereign co-investor at its back, Ineffable Intelligence is the most heavily resourced new entrant in the European AI cycle. Sesamers covers European fundraising rounds across deeptech, fintech and AI. Source: tech.eu.

Fundraising 5 days ago

Belfast's Cloudsmith has raised $72M Series C led by TCV, with Insight Partners participating, to expand its artifact management platform and secure the AI-era software supply chain.

Fundraising 5 days ago

Berlin’s VREY has raised €3.3M seed led by Rubio Impact Ventures to roll out rooftop solar software for Germany’s multi-family buildings.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.